Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

522.83
-9.7000-1.82%
Post-market: 510.00-12.8300-2.45%18:33 EDT
Volume:338.24K
Turnover:178.08M
Market Cap:22.91B
PE:18.77
High:535.33
Open:534.11
Low:520.97
Close:532.53
52wk High:549.50
52wk Low:266.98
Shares:43.83M
Float Shares:41.99M
Volume Ratio:0.54
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.86
EPS(LYR):27.86
ROE:19.71%
ROA:12.42%
PB:3.23
PE(LYR):18.77

Loading ...

Sleep Number Names Kelly F. Baker Controller and Principal Accounting Officer

Reuters
·
Mar 12

United Therapeutics Chairperson and CEO Martine A Rothblatt Disposes of Common Shares

Reuters
·
Mar 12

United Therapeutics reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%

Reuters
·
Mar 12

United Therapeutics Corp - Plans Snda Submission to FDA by Second Half of 2026 for Tyvaso in Ipf

THOMSON REUTERS
·
Mar 12

United Therapeutics Corp - Tyvaso Well-Tolerated With Safety Profile Consistent With Previous Studies

THOMSON REUTERS
·
Mar 12

United Therapeutics Corp - Teton-2 Study Met Primary Endpoint With Tyvaso Improving Absolute Fvc at Week 52

THOMSON REUTERS
·
Mar 12

United Therapeutics Corporation Announces Full Results of Teton-2 Phase 3 Clinical Trial Published in the New England Journal of Medicine

THOMSON REUTERS
·
Mar 12

Gordon Reid’s Top Picks for March 10, 2026

Bloomberg
·
Mar 11

What United Therapeutics (UTHR)'s Ralinepag Phase 3 Win and $2 Billion Buyback Mean For Shareholders

Simply Wall St.
·
Mar 10

United Therapeutics Gains on $2B Stock Buyback Authorization

Dow Jones
·
Mar 09

BRIEF-United Therapeutics Unveils $2 Bln Buyback Plan, Launches $1.5 Bln Accelerated Repurchase

Reuters
·
Mar 09

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters Into $1.5 Billion Accelerated Share Repurchase Program

THOMSON REUTERS
·
Mar 09

United Therapeutics Corp - $500 Mln Remains Available for Additional Repurchases Over One-Year Period

THOMSON REUTERS
·
Mar 09

Top United Therapeutics Insiders Quietly Cash Out in Major Stock Moves

TIPRANKS
·
Mar 06

United Therapeutics EVP and General Counsel Paul A. Mahon Disposes of Common Shares

Reuters
·
Mar 06

United Therapeutics Director Ray Kurzweil Disposes of Common Shares

Reuters
·
Mar 06

United Therapeutics Director Christopher Causey Disposes of Common Shares

Reuters
·
Mar 06

United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says

MT Newswires Live
·
Mar 06

UBS Adjusts Price Target on United Therapeutics to $705 From $655, Maintains Buy Rating

MT Newswires Live
·
Mar 05

United Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Mar 05